GVK Biosciences (GVK BIO), Asia’s leading drug discovery research and development organisation, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities. This GLP compliant facility has state-of-the-art equipment to cater to the requirements of companies engaged in the fields of drug discovery and development, agro and veterinary chemicals, cosmetics, perfumery and specialty studies.
Speaking of this development, Manni Kantipudi, CEO, GVK BIO, said, “Several of our customers requested us to extend our chemistry services to include isotope labelling services. We listened to our customers and set up this state-of-the art facility which is the largest such facility in India. The facility has received all statutory approvals from the Atomic Energy Review Board of India.”
The company provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Its discovery services consist of chemistry, biology and informatics; the development services include clinical research, clinical pharmacology and process R&D. Its diverse portfolio of nearly 200 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic and research institutions.